MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.

The nucleotide-binding-domain (NBD)-and leucine-rich repeat (LRR)-containing (NLR) family, pyrin-domain-containing 3 (NLRP3) inflammasome drives pathological inflammation in a suite of autoimmune, metabolic, malignant, and neurodegenerative diseases. Additionally, NLRP3 gain-of-function point mutati...

Full description

Bibliographic Details
Main Authors: Lieselotte Vande Walle, Irma B Stowe, Pavel Šácha, Bettina L Lee, Dieter Demon, Amelie Fossoul, Filip Van Hauwermeiren, Pedro H V Saavedra, Petr Šimon, Vladimír Šubrt, Libor Kostka, Craig E Stivala, Victoria C Pham, Steven T Staben, Sayumi Yamazoe, Jan Konvalinka, Nobuhiko Kayagaki, Mohamed Lamkanfi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-09-01
Series:PLoS Biology
Online Access:https://doi.org/10.1371/journal.pbio.3000354

Internet

https://doi.org/10.1371/journal.pbio.3000354

Similar Items